Cepheid (CPHD) Files Form 4 Insider Selling : Scott A. Campbell Sells 2,058 Shares

Cepheid (CPHD): Scott A. Campbell , Corporate VP & CRO of Cepheid sold 2,058 shares on May 3, 2016. The Insider selling transaction was reported by the company on May 3, 2016 to the Securities and Exchange Commission. The shares were sold at $27.90 per share for a total value of $57,418.41 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 3, 2016, Peter V. Farrell (EVP, Worldwide Commercial Ops) sold 390 shares at $28.90 per share price.On Apr 27, 2016, John L Bishop (Chairman of the Board and CEO) sold 110,000 shares at $35.50 per share price.Also, On Mar 2, 2016, Robert J Easton (director) sold 12,500 shares at $31.13 per share price.On Feb 9, 2016, Warren C Jr Kocmond (EVP & Chief Operating Officer) sold 292 shares at $28.53 per share price.

Shares of Cepheid (CPHD) ended Monday, May 2, 2016 session in red amid volatile trading. The shares closed down -0.09 points or -0.32% at $28.45 with 9,32,630 shares getting traded. Post opening the session at $28.76, the shares hit an intraday low of $28.23 and an intraday high of $29.6 and the price vacillated in this range throughout the day. The company has a market cap of $2,067 M and the number of outstanding shares has been calculated to be 7,26,47,648 shares. The 52-week high of Cepheid is $63.69 and the 52-week low is $26.22.

Cepheid Money Flow Index Chart

Company has been under the radar of several Street Analysts.Cepheid is Reiterated by Canaccord Genuity to Hold and the brokerage firm has raised the Price Target to $ 34 from a previous price target of $29 .The Rating was issued on Apr 14, 2016.

Cepheid is a molecular diagnostics company. The Company develops manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps including sample preparation DNA amplification and detection. The Company’s systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system which integrates sample preparation in addition to DNA amplification and detection serves reference laboratories and hospital central laboratories to satellite testing locations such as emergency departments and intensive care units within hospitals as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system which integrates DNA amplification and detection to allow rapid analysis of a sample.

Leave a Reply

Cepheid - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cepheid. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.